Effect of flavonoids and CYP3A4 variants on midostaurin metabolism

被引:5
|
作者
Xu, Ren-ai [1 ,2 ]
Li, Qing-qing [2 ]
Gao, Nan-yong [2 ]
Wang, Jing [2 ]
Li, Xin-yue [2 ]
Ye, Feng [2 ]
Ni, Jin-huan [2 ]
Hu, Guo-xin [2 ,3 ]
Qian, Jian-chang [2 ,3 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325000, Peoples R China
[2] Wenzhou Med Univ, Inst Mol Toxicol & Pharmacol, Sch Pharmaceut Sci, Wenzhou, Zhejiang, Peoples R China
[3] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Peoples R China
基金
中国国家自然科学基金;
关键词
Flavonoids; Midostaurin; Genetic polymorphism; Myricetin; Interaction; ACUTE MYELOID-LEUKEMIA; GENETIC POLYMORPHISMS; IN-VIVO; PHARMACOKINETICS; ANTIBACTERIAL; INHIBITION; MYRICETIN; APIGENIN;
D O I
10.1016/j.fct.2023.113669
中图分类号
TS2 [食品工业];
学科分类号
0832 ;
摘要
The objective of this study was to determine the effect of flavonoids on midostaurin disposition considering co -administration and metabolic enzyme gene polymorphism. Enzymatic incubation assays were performed in vitro, while in vivo experiments were conducted in Sprague-Dawley rats. The analytes were determined via UPLC-MS/ MS. We found that myricetin was the most potent among the investigated 10 flavonoids in suppressing the metabolism of midostaurin, with an IC50 at a low mu M level. After co-administration of midostaurin and myricetin, the plasma concentration of midostaurin's primary metabolite CGP62221 was reduced corresponding to myr-icetin exposure. Furthermore, CYP3A4 homologous rat protein CYP3A2 was reduced significantly in the co -administration group. Thereafter, the kinetic parameters of 23 recombinant human CYP3A4 variants were determined using midostaurin. The relative intrinsic clearance varied from 269.63% in CYP3A4.29-8.95% in CYP3A4.17. In addition, the inhibitory potency of myricetin was substantially different for CYP3A4.29 and CYP3A4.17 compared with wild type, with IC50 values of 9.85 +/- 0.27 mu M and 90.99 +/- 16.13 mu M, respectively. Collectively, our data demonstrated that flavonoids, particularly myricetin, can inhibit the metabolism of mid-ostaurin. Additionally, CYP3A4 genetic polymorphism may contribute to stratification of midostaurin blood exposure.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Concomitant Use of Midostaurin with Strong CYP3A4 Inhibitors: An Analysis from the Ratify Trial
    Ouatas, Taoufik
    Duval, Vincent
    Sinclair, Karen
    Berkowitz, Noah
    BLOOD, 2017, 130
  • [32] Time-dependent inhibition of CYP3A4-mediated midazolam metabolism by macrolide antibiotics in CYP3A4 genetic variants: Comparison with testosterone metabolism
    Akiyoshi, Takeshi
    Naitou, Rina
    Imaoka, Ayuko
    Miyazaki, Mitsue
    Guengerich, F. Peter
    Nakamura, Katsunori
    Yamamoto, Koujiro
    Ohtani, Hisakazu
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2021, 59 (12) : 745 - 752
  • [33] THE PROTEIN KINASE INHIBITORS MIDOSTAURIN AND NINTEDANIB ARE TIME-DEPENDENT INHIBITORS OF CYP3A4
    Filppula, A.
    Mustonen, T.
    Backman, J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 12 - 12
  • [34] Effect of mibefradil on CYP3A4 in vivo
    Veronese, ML
    Gillen, LP
    Dorval, EP
    Hauck, WW
    Waldman, SA
    Greenberg, HE
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (10): : 1091 - 1100
  • [35] Pioglitazone: Effect on CYP3A4 activity
    Nowak, SN
    Edwards, DJ
    Clarke, A
    Anderson, GD
    Jaber, LA
    JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (12): : 1299 - 1302
  • [36] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism
    McGraw, Joseph
    Cherney, Mitchell
    Bichler, Katherine
    Gerhardt, Armin
    Nauman, Mirielle
    TOXICOLOGY LETTERS, 2019, 315 : 9 - 13
  • [37] The Relative Contributions of CYP3A4 and CYP3A5 to the Metabolism of Vinorelbine
    Topletz, Ariel R.
    Dennison, Jennifer B.
    Barbuch, Robert J.
    Hadden, Chad E.
    Hall, Stephen D.
    Renbarger, Jamie L.
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (09) : 1651 - 1661
  • [38] Genetic Variants of CYP3A4 and CYP3A5 in Cynomolgus and Rhesus Macaques
    Uno, Yasuhiro
    Matsushita, Akinori
    Osada, Naoki
    Uehara, Shotaro
    Kohara, Sakae
    Nagata, Ryoichi
    Fukuzaki, Koichiro
    Utoh, Masahiro
    Murayama, Norie
    Yamazaki, Hiroshi
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (02) : 209 - 214
  • [39] Functional Analysis of Wild-Type and 27 CYP3A4 Variants on Dronedarone Metabolism In vitro
    Wang, Chen-Chen
    Lan, Tian
    CURRENT DRUG METABOLISM, 2022, 23 (07) : 562 - 570
  • [40] The effect of genetic variants in the transcription factor TSPYL family on the CYP3A4 mediated cyclosporine metabolism in kidney transplant patients
    Zhai, Qinglian
    Moes, Dirk Jan A. R.
    van Gelder, Teun
    van Der Lee, Maaike
    Sanders, Jan-Stephan
    Bemelman, Frederike J.
    de Fijter, Johan W.
    Klein, Kathrin
    Schwab, Matthias
    Swen, Jesse J.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (02):